Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate First Tracks Biotherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding First Tracks Biotherapeutics, Inc.’s stock price such as:

• First Tracks Biotherapeutics, Inc.’s current stock price and volume
• Why First Tracks Biotherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TRAX from analysts
• TRAX’s stock price momentum as measured by its relative strength

About First Tracks Biotherapeutics, Inc. (TRAX)

Before we jump into First Tracks Biotherapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Want to learn more about First Tracks Biotherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about First Tracks Biotherapeutics, Inc..

First Tracks Biotherapeutics, Inc.’s Stock Price as of Market Close

As of September 03, 2026, 4:00 PM, CST, First Tracks Biotherapeutics, Inc.’s stock price was $42.510.

First Tracks Biotherapeutics, Inc. is down 6.12% from its previous closing price of $45.280.

During the last market session, First Tracks Biotherapeutics, Inc.’s stock traded between $42.290 and $45.560. Currently, there are approximately 35.00 million shares outstanding for First Tracks Biotherapeutics, Inc..

First Tracks Biotherapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

First Tracks Biotherapeutics, Inc. Stock Price History

First Tracks Biotherapeutics, Inc.’s (TRAX) price is currently up 1.6% so far this month.

During the month of September, First Tracks Biotherapeutics, Inc.’s stock price has reached a high of $47.980 and a low of $40.750.

Over the last year, First Tracks Biotherapeutics, Inc. has hit prices as high as $49.911 and as low as $14.720.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused First Tracks Biotherapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there was 1 analyst who downgraded First Tracks Biotherapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate First Tracks Biotherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on First Tracks Biotherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about First Tracks Biotherapeutics, Inc. (TRAX) by visiting AAII Stock Evaluator.

Relative Price Strength of First Tracks Biotherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, First Tracks Biotherapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how First Tracks Biotherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

First Tracks Biotherapeutics, Inc. Stock Price: Bottom Line

As of September 3, 2026, First Tracks Biotherapeutics, Inc.’s stock price is $42.510, which is down 6.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like First Tracks Biotherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.